Podcasts
Listen to the latest hemonc news from international experts
The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer post-infection outcomes. In this podcast, Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, chairs an exciting discussion with Jan Philipp Bewersdorf, Yale University and Yale Cancer Center, New Haven, CT, Rory Shallis, MD, Yale University and Yale Cancer Center, New Haven, CT, and John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY. These speakers discuss their recent collaborative publication in Lancet Hematology, evaluating the management of adult patients with acute leukemias and myeloid neoplasms in the COVID-19 era.
Date: 28th July 2020
